Peter Drueckes
Impact in
- Hematology top 5%
- Chronic Myeloid Leukemia Treatments
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Papers in
- Oncology 11
- HER2/EGFR in Cancer Research 3
- Peptidase Inhibition and Analysis 3
-
- Chronic Myeloid Leukemia Treatments 5
- Co-authors
- Pascal Furet (5 shared papers)Markus Wartmann (3 shared papers)Reinhard Schinzel (5 shared papers)D. Palm (3 shared papers)Vincent Bordas (1 shared paper)HERBERT A. SCHMID (1 shared paper)Dirksen E. Bussiere (1 shared paper)Joerg Berghausen (1 shared paper)
- Journals
- Bioorganic & Medicinal Chemistry Letters (3 papers)ACS Chemical Biology (2 papers)Cancer Research (2 papers)Journal of Medicinal Chemistry (2 papers)European Journal of Medicinal Chemistry (2 papers)
- Partner nations
- SwitzerlandGermanyUnited States
In The Last Decade
Peter Drueckes
28 papers receiving 1.8k citations
Peter Drueckes's Hit Papers
Peers
Comparison fields: 5 of 104
- Hematology 319
- Genetics 238
- Oncology 415
- Molecular Biology 1.0k
- Pathology and Forensic Medicine 201
Countries citing papers authored by Peter Drueckes
This map shows the geographic impact of Peter Drueckes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Drueckes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Drueckes more than expected).
Fields of papers citing papers by Peter Drueckes
This network shows the impact of papers produced by Peter Drueckes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Drueckes. The network helps show where Peter Drueckes may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Drueckes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 422 | |
| 2 | Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 Hit paper breakdown → | 2018 | 360 |
| 3 | 2009 | 198 | |
| 4 | 2011 | 112 | |
| 5 | 2010 | 104 | |
| 6 | 2014 | 104 | |
| 7 | 2007 | 101 | |
| 8 | 2015 | 91 | |
| 9 | 1995 | 77 | |
| 10 | 1997 | 55 | |
| 11 | 1999 | 45 | |
| 12 | 2010 | 37 | |
| 13 | 2016 | 35 | |
| 14 | 2010 | 25 | |
| 15 | 2008 | 23 | |
| 16 | 1991 | 22 | |
| 17 | 2010 | 22 | |
| 18 | 1996 | 16 | |
| 19 | 2012 | 15 | |
| 20 | 2010 | 13 |
About Peter Drueckes
Peter Drueckes is a scholar working on Oncology, Hematology, Biotechnology, Genetics and Molecular Biology, having authored 28 papers that have together received 1.9k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (5 papers), Enzyme Production and Characterization (4 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers), Microtubule and mitosis dynamics (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Enzyme Structure and Function (3 papers), HER2/EGFR in Cancer Research (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Hematology (319 citations), Genetics (238 citations), Oncology (415 citations), Molecular Biology (1.0k citations) and Pathology and Forensic Medicine (201 citations). Peter Drueckes has collaborated with scholars based in Switzerland, Germany and United States. Frequent co-authors include Pascal Furet, Markus Wartmann, Reinhard Schinzel, D. Palm, Vincent Bordas, HERBERT A. SCHMID, Dirksen E. Bussiere, Joerg Berghausen, Christelle Stamm and Alfred G. Zimmerlin. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, ACS Chemical Biology, Cancer Research, Journal of Medicinal Chemistry and European Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.